Imatinib is used in the treatment of chronic myelogenous leukemia in early adults.
Imatinib is a novel 2-aniline pyrimidine tyrosine kinase inhibitor. It can effectively inhibit the activity of Bcr-abl tyrosine kinase, which is a product of abnormal expression of the Ph chromosome of chronic myeloid leukemia (CML), at the cellular level, so imatinib can selectively inhibit the proliferation and induce apoptosis of Ber-abl positive cell line cells and cells of patients with chronic myeloid leukemia. In addition, imatinib can also inhibit platelet-derived growth factor (PDGF) receptors, stem cell factor (SCF), and tyrosine kinases of c-Kit receptors, thereby inhibiting cell behavior mediated by PDGF and stem cell factors, but does not affect signal transduction of other stimulating factors such as epidermal growth factor.
|Appearance||White or almost white powder||White powder|
|Residue on ignition||≤0.1%||0.03%|
|Appearance:||White or almost white powder|
|Package details:||1kg/foil bag|
High quality & competitive price
Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!